Search - tctmd.com

Displaying 1 - 20 of 615

Sort: Relevancy | Date

Presentation

Clinical Outcomes According to FFR or iFR in Deferred Lesions

December 01, 2017

Presentation AHA 2017

Insights from the FOURIER Trial

Presenter: Marc P. Bonaca

November 15, 2017

Presentation AHA 2017

Impact of Regionalization of ST Elevation Myocardial Infarction Care

Presenter: James G. Jollis

November 14, 2017

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation AHA 2017

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Presenter: Kenneth W. Mahaffey

November 14, 2017

Presentation AHA 2017

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Presenter: Louise Bowman

November 14, 2017

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Presentation Cardiovascular Interventions 2017

How Me The Data: Key Clinical Trials of 2017

Presenter: Curtiss T. Stinis

November 09, 2017

Presentation TCT 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, William F. Fearon

November 02, 2017

Presentation TCT 2017

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Rasha Al-Lamee

November 02, 2017

Presentation TCT 2017

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Presenter: Saibal Kar

November 02, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Presenter: Eberhard Grube, James B. Hermiller Jr., Hemal Gada

November 01, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

PFO Closure for Hypoxemia: Who Responds and Who Does Not? Designing a Trial to Prove the Concept

Presenter: Mark Reisman, Brian K. Whisenant, Joseph Kay

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

Presenter: Mark Reisman, Brian K. Whisenant, Robert J. Sommer

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

VTE and PFO Closure: Device? Anticoagulation? Both?

Presenter: Mark Reisman, Brian K. Whisenant, Christian Spies

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Advertisement

Clinical Outcomes According to FFR or iFR in Deferred Lesions

Insights from the FOURIER Trial

Impact of Regionalization of ST Elevation Myocardial Infarction Care

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

How Me The Data: Key Clinical Trials of 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

PFO Closure for Hypoxemia: Who Responds and Who Does Not? Designing a Trial to Prove the Concept

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

The Clinical Relevance of Valve Leaflet Thickening after TAVR

VTE and PFO Closure: Device? Anticoagulation? Both?

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content